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Fetuin-A is a serum protein that inhibits vascular calcification
such that lower levels are associated with a higher
prevalence of vascular calcification and mortality risk among
end-stage renal disease populations. We analyzed data of
822 persons in the Modification of Diet in Renal Disease
study, a randomized, controlled trial of persons with
predominantly non-diabetic stage 3–4 chronic kidney disease
(CKD). Serum fetuin-A levels were measured in baseline
serum. Survival status and cause of death were determined
by the National Death Index. Cox proportional hazard models
evaluated the association of fetuin-A levels with all-cause and
cardiovascular mortality. Glomerular filtration ranged from 13
to 55 ml per min per 1.73 m2. During a median follow-up of
9.5 years, 25% of persons died from any cause and 12% died
from a cardiovascular cause. Compared to the lowest tertile,
no association was found between the highest fetuin-A
tertile and all-cause or cardiovascular mortality. Similarly, no
association was found between fetuin-A as a continuous
variable and all-cause or cardiovascular mortality. Our study
shows that serum fetuin-A levels are not related to all-cause
or cardiovascular mortality among persons with
predominantly non-diabetic stage 3 or 4 CKD.
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Persons with end-stage renal disease (ESRD) requiring
maintenance dialysis demonstrate extensive dystrophic vas-
cular calcification,1–5 and its presence and severity is strongly
associated with mortality.6–8 Recent research has demon-
strated that vascular calcification is actively regulated,9 and
therefore potentially modifiable1,4 rather than a passive
process as believed previously.10
At physiologic pH, calcium and phosphorus concentra-
tions within the normal range are nearly high enough to
spontaneously precipitate, so serum-based inhibitors of
precipitation appear necessary for homeostasis.11 Fetuin-A
(also called a-2 Heremans–Schmid glycoprotein) is a hepatic
secretory protein that is found in high concentrations in
human serum.12 Fetuin-A is a potent inhibitor of vascular
calcification;13 it reversibly complexes with calcium and
phosphorus and increases their respective serum solubi-
lity14,15 in a mechanism reminiscent to that by which
apolipoproteins solubilize lipids.16 Incubation of fetuin-A
with calcium and phosphorus at physiologic pH prevents
crystallization for more than 9 days, whereas the minerals
crystallized within hours in its absence.14 Similar effects
have been demonstrated in human serum.15 Among popu-
lations with ESRD, serum fetuin-A concentrations are
inversely correlated with vascular and cardiac valvular
calcification,17 and lower concentrations have consistently
predicted higher all-cause and cardiovascular mortality
risk.15,18–20
Persons with stage 3–4 chronic kidney disease (CKD) also
have high prevalence of vascular calcification21 and high risk
of cardiovascular mortality.22 To our knowledge, there are no
previous studies evaluating whether serum fetuin-A concen-
trations are associated with all-cause or cardiovascular
mortality among persons with stage 3–4 CKD. To that end,
we determine the association of serum fetuin-A concentra-
tions with cardiovascular and all-cause mortality among
persons with predominantly non-diabetic stage 3–4 CKD
who participated in the Modification of Diet in Renal Disease
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(MDRD) Study. We hypothesized that lower serum fetuin-A
concentrations would be associated with higher all-cause and
cardiovascular mortality, and that the association would be
independent of traditional cardiovascular risk factors and
severity of baseline kidney function.
RESULTS
Baseline characteristics
The mean age of the 822 persons study sample was 52 years,
60% were male, and 85% were white. The mean7s.d.
iothalamate measured glomerular filtration rate (GFR) was
33711 ml per min per 1.73 m2, with a range from 13 to 55 ml
per min per 1.73 m2, and median proteinuria was 330 mg g1
creatinine (interquartile range¼ 10–1500 mg g1). None of
the persons was receiving maintenance dialysis at baseline.
The etiology of kidney disease was due to polycystic kidney
disease in 24%, glomerular disease in 32%, and other causes
in 45%. Forty-three subjects (5%) had diabetes mellitus. The
mean7s.d. fetuin-A concentration was 0.9870.34 g l1, and
the values were approximately normally distributed (Fig-
ure 1). Compared to persons with fetuin-A concentrations
among the lowest tertile, persons with higher fetuin-A
concentrations were younger and had higher serum choles-
terol concentrations. Other demographic variables, medical
history, and kidney function measurements were similar
across fetuin-A tertiles (Table 1).
All-cause mortality
The median follow-up time was 9.5 years, during which 204
(25%) of the persons died. Kaplan–Meier survival curves did
not demonstrate differences by fetuin-A tertiles for all-cause
mortality (Figure 2). Similarly, the relative hazards were
similar across fetuin-A tertiles in unadjusted and adjusted
Cox proportional hazards models (Table 2). When modeled
as a continuous variable (per s.d. (0.34 g l1) increase),
fetuin-A had no significant association with mortality, and
the point estimated was nearly unity (adjusted HR (hazard
ratio) 1.03; 95% CI¼ 0.89–1.19; P¼ 0.72). We found no
evidence of effect modification on the basis of age,
iothalamate GFR, obesity, or tobacco use (P-values for
interaction all 40.43).
Table 1 | Baseline characteristics by tertiles of fetuin-A
Tertile I Tertile II Tertile III P-value
0.32–0.83 g l1 (n=275) 0.84–1.06 g l1 (n=273) 1.07–2.65 g l1 (n=274)
Fetuin-A7s.d. (g l1) 0.6770.13 0.9470.06 1.3370.31
Demographics
Age7s.d. (years) 53712 51712 51712 0.07
Female (%) 100 (36) 122 (45) 104 (38) 0.11
Caucasian (%) 236 (86) 233 (85) 231 (84) 0.99
Cardiovascular risk factors
History of CAD (%) 33 (12) 25 (9) 22 (8) 0.27
History of diabetes (%) 14 (5) 19 (7) 10 (4) 0.22
History of hypertension (%) 229 (83) 239 (88) 239 (87) 0.28
Body mass index7s.d. (g m2) 2774 2774 2774 0.92
Total cholesterol7s.d. (mg dl1) 210742 220747 220745 0.01
LDL cholesterol7s.d. (md dl1) 144739 149743 150742 0.19
C-reactive protein (mg dl1)a 0.3 [0.1–0.7] 0.2 [0.1–0.6] 0.2 [0.1–0.6] 0.53
Kidney disease measurements
Iothalamate GFR7s.d. (ml per min per 1.73 m2) 32712 32712 34712 0.20
Proteinuria (g day1)a 0.3 [0.1–1.4] 0.3 [0.1–1.5] 0.4 [0.1–1.6] 0.47
Calcium7s.d. (mg/dl) 9.170.6 9.170.5 9.270.6 0.27
Phosphorus7s.d. (mg dl1) 3.870.7 3.970.7 3.870.6 0.12
Kidney disease diagnosis
Glomerular disease (%) 65 (24) 90 (32) 118 (43)
Polycystic kidney disease (%) 64 (23) 86 (31) 124 (45) 0.98
Other (%) 66 (24) 84 (31) 124 (45)
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Figure 1 | Distribution of serum fetuin-A concentrations in the
MDRD study cohort.
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Cardiovascular mortality
During follow-up, 99 (12%) persons died of cardiovascular
cause. Kaplan–Meier survival curves for cardiovascular
mortality did not differ across fetuin-A tertiles (Figure 3).
As with all-cause mortality, unadjusted and adjusted relative
hazards for cardiovascular mortality were similar across
fetuin-A tertiles (Table 3). When evaluated as a continuous
predictor variable (per s.d. increase), fetuin-A had no
significant association with cardiovascular mortality (ad-
justed HR 1.03; 95% CI¼ 0.83–1.29; P¼ 0.77). We observed
no effect modification on the basis of age, iothalamate GFR,
obesity, or tobacco use (P-values for interaction all 40.41).
DISCUSSION
In this study, we demonstrate that serum concentrations of
fetuin-A were not associated with all-cause or cardiovascular
mortality among persons with stage 3–4 CKD who partici-
pated in the MDRD study.
Fetuin-A is a novel serum-based inhibitor of dystrophic
vascular and valvular calcification. It is produced in the liver,
and is secreted into circulation,13 where it is found in high
concentrations.12,19 Fetuin-A knockout mice demonstrate
wide-spread soft tissue, vascular, and valvular calcification.13,23
Structure and function studies suggest that fetuin-A deficiency
leads to this phenotype through at least two distinct
mechanisms. First, in serum, it interacts with calcium and
phosphorus forming ‘calciproteins,’ increasing the solubility of
these minerals by mechanisms reminiscent to that by which
apolipoproteins solubilize lipids.14,16 Second, fetuin-A appears
to have local inhibitory effects at the site of ectopic
mineralization within the vascular wall. Vascular smooth
muscle cells are capable of internalizing fetuin-A from the
extracellular space, and re-secrete fetuin-A within matrix
vesicles. Fetuin-A within matrix vesicles abrogates their ability
to function as a nidus for ectopic calcification within the
vascular wall.24 Because vascular smooth muscle cells do not
produce fetuin-A, the local inhibitory effects on mineralization
are likely derived from serum sources of fetuin-A.24
Vascular calcification is highly prevalent in persons with
ESRD,1,4,5 and its presence and severity predicts all-cause and
cardiovascular mortality.6–8 Earlier literature has demons-
trated that fetuin-A concentrations are inversely correlated
with vascular and valvular calcification,17,20 and lower serum
concentrations have consistently predicted all-cause and
cardiovascular mortality in ESRD population.15,18–20 Because
persons with stage 3–4 CKD are also at high risk of
cardiovascular and all-cause mortality,22 and because stage
3–4 CKD is associated with highly prevalent vascular
calcification,21,25,26 we hypothesize that fetuin-A would also
represent a novel biomarker for mortality in persons with
stage 3–4 CKD. However, our results demonstrated no such
association. Moreover, the association of fetuin-A with
mortality was absent among persons with advanced age,
more advanced CKD, tobacco use, and obesity—characte-
ristics associated with higher prevalence of vascular calcifica-
tion in previous epidemiologic studies.
Table 2 | Association of fetuin-A tertiles and all-cause
mortality
Tertile I Tertile II Tertile III
Range 0.32–0.83 g l1 0.84–1.06 g l1 1.07–2.65 g l1
Unadjusted 1.00 (reference) 1.07 (0.78–1.49) 0.80 (0.57–1.13)
Demographic adjusteda 1.00 (reference) 1.36 (0.98–1.89) 0.98 (0.69–1.39)
Multivariable adjustedb 1.00 (reference) 1.42 (1.00–2.01) 1.01 (0.71–1.46)
CRP, C-reactive protein; GFR, glomerular filtration rate.
aAdjusted for age, gender, and race/ethnicity.
bAdjusted for demographic variables and iothalamate GFR, history of diabetes,
hypertension, log (CRP), proteinuria, randomized blood pressure group, and protein
intake group.
1.00

















Figure 2 | Kaplan–Meier survival curve for all-cause mortality by
fetuin-A tertiles.
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Figure 3 | Kaplan–Meier survival curve for cardiovascular
mortality by fetuin-A tertiles.
Table 3 | Association of fetuin-A tertiles and cardiovascular
mortality
Tertile I Tertile II Tertile III
Range 0.32–0.83 g l1 0.84–1.06 g l1 1.07–2.65 g l1
Unadjusted 1.00 (reference) 1.00 (0.62–1.60) 0.84 (0.52–1.38)
Demographic adjusteda 1.00 (reference) 1.30 (0.81–2.10) 1.12 (0.68–1.83)
Multivariable adjustedb 1.00 (reference) 1.22 (0.74–2.00) 1.03 (0.63–1.72)
CRP, C-reactive protein; GFR, glomerular filtration rate.
aAdjusted for age, gender, and race/ethnicity.
bAdjusted for demographic variables and iothalamate GFR, history of diabetes,
hypertension, log (CRP), proteinuria, randomized blood pressure group, and protein
intake group.
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There are several possible explanations for the lack of
association of fetuin-A with all-cause and cardiovascular
mortality in this study. First, it is unknown whether vascular
calcification is associated with all-cause and cardiovascular
mortality among persons with stage 3–4 CKD. Therefore,
fetuin-A could have a strong association with vascular
calcification in the setting of stage 3–4 CKD, but not predict
cardiovascular and all-cause mortality. While possible, a lack
of association of vascular calcification with mortality among
persons with stage 3–4 CKD seams unlikely, because coronary
artery calcification has consistently predicted cardiovascular
events and mortality among persons without kidney
disease,27–33 and among persons with ERSD.7,8 Second,
serum fetuin-A concentrations observed in the MDRD study
cohort were more similar to concentrations reported
previously in healthy subjects,19 than to concentrations
observed among ESRD populations, where serum concentra-
tions are lower.15,18–20 Kidney function was similar across
fetuin-A tertiles in this study. This observation is consistent
with our previous studies demonstrating no changes in
serum fetuin-A concentrations across the spectrum from
normal kidney function to stage 3 CKD.12 Therefore, it is
possible that fetuin-A concentrations may not be associated
with increased mortality risk until they drop below a certain
threshold, which may be uncommon among non-ESRD
populations. Because the molecular size of fetuin-A is
64 kDa,16 it is too large to be removed by conventional
hemodialysis membranes, so the mechanisms by which lower
serum concentrations develop among ESRD populations is
uncertain; however, it is possible that other factors other than
clearance related to dialysis therapy, such as vitamin D
administration or changes in serum calcium or phosphorus
concentrations, might affect fetuin-A concentrations.34 Alter-
natively, fetuin-A concentrations may be increased in stage
3–4 CKD to protect against calcification. The extent of factors
promoting vascular calcification in ESRD may be sufficiently
severe to exhaust the liver’s ability to produce sufficient
fetuin-A, thereby resulting in lower serum concentrations in
this population. It is possible that the absent associations of
fetuin-A with mortality in this study reflects features of the
population being studied, as trial persons may differ from the
general population of persons with stage 3–4 CKD. Persons in
the MDRD study were relatively healthy, predominantly
white, had low prevalence of diabetes, and were excluded if
they had severe proteinuria. Therefore, these observations
require confirmation in other populations among persons
with stage 3–4 CKD. Finally, the lack of an association could
have occurred due to inadequate statistical power. However,
on the basis of the models in which fetuin-A served as a
continuous predictor variable, the 95% confidence intervals
exclude a relative hazard greater than 1.2 for all-cause
mortality and 1.3 for cardiovascular mortality (per s.d.
change) in fetuin-A. Therefore, any missed association would
be modest, at best.
Strengths of this study include the large sample size of
persons with stage 3–4 CKD, long follow-up time, and
detailed ascertainment of severity of kidney disease and other
potential confounding variables. However, several important
limitations should be recognized when interpreting our
results. In addition to statistical power, and factors unique to
the MDRD study cohort described above, direct measures of
vascular calcification were not available in the MDRD study
cohort. Therefore, whether the lack of an association of
fetuin-A with all-cause and cardiovascular mortality reflects
an unusually low prevalence of vascular calcification in this
cohort could not be determined.
In conclusion, serum fetuin-A concentrations were not
associated with all-cause or cardiovascular mortality among
persons in the MDRD study with stage 3–4 CKD. Whether
the prevalence and severity of vascular calcification predicts
all-cause or cardiovascular mortality among persons with
stage 3–4 CKD, independent of traditional cardiovascular risk
factors should be evaluated in future studies.
MATERIALS AND METHODS
Study persons
The MDRD study, conducted from 1989 to 1993, was a randomized,
controlled trial designed to determine the effect of dietary protein
restriction and blood pressure control on the progression of kidney
disease. Details of the study have been published previously.35–37
Briefly, persons age was 18–70 years with a serum creatinine
concentration of 1.2–7.0 mg dl1 in women and 1.4–7.0 mg dl1 in
men, and a mean arterial pressure of 125 mm Hg or less were
considered eligible. Candidates were excluded for pregnancy, body
weight less than 80 or greater than 160% of standard body weight,
diabetes mellitus requiring insulin therapy, urinary protein excretion
exceeding 10 g per day, previous renal transplantation, class 3 or 4
congestive heart failure, renal artery stenosis, or frequent hospitali-
zations.36 Five hundred and eighty five persons with baseline GFR of
25–55 ml per min per 1.73 m2 were randomized in study A, and 255
persons with baseline GFR of 13–24 ml per min per 1.73 m2 were
randomized in study B. Within each study, persons were randomly
allocated to one of the two levels of blood pressure control, and to
one of the two dietary interventions. Persons in both studies were
combined for the current analysis. A total of 840 persons were
recruited. Persons among whom frozen serum was not available
were excluded (n¼ 18), resulting in a study sample of 822 subjects
for the current analysis.
Serum fetuin-A
Study persons provided fasting serum at their baseline study visit,
which was frozen at 701C. Fetuin-A concentrations were measured
in baseline serum using a human fetuin-A enzyme-linked im-
munosorbent assay kit (Epitope Diagnositics, San Deigo, CA, USA).
The assay uses a two-site ‘sandwich’ technique with two polyclonal
antibodies that bind to different epitopes of human fetuin-A.
Fetuin-A measurements were made at the Laboratory for Clinical
Biochemistry Research at the University of Vermont, and were made
in duplicate, and the average measure was used for each participant.
The intra- and interassay coefficients of variation at the University of
Vermont were 3.3 and 3.4%, respectively.
All-cause and cardiovascular mortality
Survival status and cause of death were ascertained from the
National Death Index. A death was ascribed to cardiovascular
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disease if the primary cause of death was International Classification
of Disease, 9th revision (ICD-9) code 390–459 or if kidney disease
was listed as the primary cause of death and cardiovascular disease
was the secondary cause. Survival time was defined as the time
from randomization to death or end of follow-up (31 December
2000). Data collection procedures were approved by the Cleveland
Clinic and Tufts-New England Medical Center Institutional Review
Boards.
Statistical analysis
Differences in baseline characteristics were compared according to
tertiles of fetuin-A using analysis of variance or the Kruskal–Wallis
test for continuous variables and the w2 test or Fisher’s exact test for
categorical variables, as appropriate. Cox proportional hazards
models evaluated the associations of fetuin-A with all-cause and
cardiovascular mortality, initially without adjustment, and subse-
quently adjusted for candidate confounding variables that were
selected a priori on the basis of previous published research. The first
adjusted model, termed ‘demographic adjusted model’ adjusted for
age, gender, and race/ethnicity. The second model, termed ‘fully
adjusted model’ adjusted for the demographic variables as well
as iothalamate-measured GFR, history of diabetes, history of hyper-
tension, log-transformed C-reactive protein concentrations, log-
transformed urinary protein excretion, and randomization assign-
ment to blood pressure strata and dietary protein intake. Fetuin-A
was evaluated both as a continuous predictor (per s.d. increase) and
categorized by tertiles. In addition, we evaluated for effect
modification in the association of fetuin-A with each outcome by
several key variables that were selected a priori because they
predicted vascular calcification in previous research (age, iothala-
mate GFR, obesity, and tobacco use).
Proportional hazards assumptions were assessed by visually
inspecting log-minus-log plots and plots of Schoenfeld residuals
versus survival time for the association of fetuin-A tertiles with each
outcome. No violations were observed. Two-tailed P-values o0.05
were considered statistically significant. Analyses were performed
using the Stata statistical software version 9, (College Station, TX,
USA).
REFERENCES
1. Block GA, Spiegel DM, Ehrlich J et al. Effects of sevelamer and calcium on
coronary artery calcification in patients new to hemodialysis. Kidney Int
2005; 68: 1815–1824.
2. Braun J, Asmus HG, Holzer H et al. Long-term comparison of a calcium-
free phosphate binder and calcium carbonate—phosphorus metabolism
and cardiovascular calcification. Clin Nephrol 2004; 62: 104–115.
3. Braun J, Oldendorf M, Moshage W et al. Electron beam computed
tomography in the evaluation of cardiac calcification in chronic dialysis
patients. Am J Kidney Dis 1996; 27: 394–401.
4. Chertow GM, Burke SK, Raggi P. Sevelamer attenuates the progression of
coronary and aortic calcification in hemodialysis patients. Kidney Int 2002;
62: 245–252.
5. Goodman WG, Goldin J, Kuizon BD et al. Coronary–artery calcification in
young adults with end-stage renal disease who are undergoing dialysis.
N Engl J Med 2000; 342: 1478–1483.
6. Blacher J, Guerin AP, Pannier B et al. Arterial calcifications, arterial stiffness
and cardiovascular risk in end-stage renal disease. Hypertension 2001; 38:
938–942.
7. Block GA, Raggi P, Bellasi A et al. Mortality effect of coronary calcification
and phosphate binder choice in incident hemodialysis patients. Kidney Int
2007.
8. Matsuoka M, Iseki K, Tamashiro M et al. Impact of high coronary artery
calcification score (CACS) on survival in patients on chronic hemodialysis.
Clin Exp Nephrol 2004; 8: 54–58.
9. Giachelli CM, Speer MY, Li X et al. Regulation of vascular calcification:
roles of phosphate and osteopontin. Circ Res 2005; 96: 717–722.
10. Cozzolino M, Dusso AS, Slatopolsky E. Role of calcium-phosphate product
and bone-associated proteins on vascular calcification in renal failure.
J Am Soc Nephrol 2001; 12: 2511–2516.
11. Ketteler M, Schlieper G, Floege J. Calcification and cardiovascular health.
New insights into an old phenomenon. Hypertension 2006; 47:
1027–1034.
12. Ix JH, Chertow GM, Shlipak MG et al. Fetuin-A and kidney function in
persons with coronary artery disease—data from the heart and soul
study. Nephrol Dial Transplant 2006; 21: 2144–2151.
13. Schafer C, Heiss A, Schwarz A et al. The serum protein alpha
2-Heremans–Schmid glycoprotein/fetuin-A is a systemically acting
inhibitor of ectopic calcification. J Clin Invest 2003; 112: 357–366.
14. Price PA, Lim JE. The inhibition of calcium phosphate precipitation by
fetuin is accompanied by the formation of a fetuin–mineral complex.
J Biol Chem 2003; 278: 22144–22152.
15. Ketteler M, Bongartz P, Westenfeld R et al. Association of low fetuin-A
(AHSG) concentrations in serum with cardiovascular mortality in
patients on dialysis: a cross-sectional study. Lancet 2003; 361:
827–833.
16. Heiss A, DuChesne A, Denecke B et al. Structural basis of calcification
inhibition by alpha 2-HS glycoprotein/fetuin-A. Formation of colloidal
calciprotein particles. J Biol Chem 2003; 278: 13333–13341.
17. Moe SM, Reslerova M, Ketteler M et al. Role of calcification inhibitors in
the pathogenesis of vascular calcification in chronic kidney disease (CKD).
Kidney Int 2005; 67: 2295–2304.
18. Honda H, Qureshi AR, Heimburger O et al. Serum albumin, C-reactive
protein, interleukin 6, and fetuin a as predictors of malnutrition,
cardiovascular disease, and mortality in patients with ESRD. Am J Kidney
Dis 2006; 47: 139–148.
19. Stenvinkel P, Wang K, Qureshi AR et al. Low fetuin-A levels are associated
with cardiovascular death: impact of variations in the gene encoding
fetuin. Kidney Int 2005; 67: 2383–2392.
20. Wang AY, Woo J, Lam CW et al. Associations of serum fetuin-A with
malnutrition, inflammation, atherosclerosis and valvular calcification
syndrome and outcome in peritoneal dialysis patients. Nephrol Dial
Transplant 2005; 20: 1676–1685.
21. Russo D, Palmiero G, De Blasio AP et al. Coronary artery calcification in
patients with CRF not undergoing dialysis. Am J Kidney Dis 2004; 44:
1024–1030.
22. Go AS, Chertow GM, Fan D et al. Chronic kidney disease and the risks of
death, cardiovascular events and hospitalization. N Engl J Med 2004; 351:
1296–1305.
23. Westenfeld R SR, Schafer C, Brandenburg V et al. The impact of fetuin-A
phosphate and uremia on the induction of extraosseous calcification in
mice. J Am Soc Nephrol 2004; 15: 270A.
24. Reynolds JL, Skepper JN, McNair R et al. Multifunctional roles for serum
protein fetuin-A in inhibition of human vascular smooth muscle cell
calcification. J Am Soc Nephrol 2005; 16: 2920–2930.
25. Fox CS, Larson MG, Keyes MJ et al. Kidney function is inversely associated
with coronary artery calcification in men and women free of
cardiovascular disease: the Framingham Heart Study. Kidney Int 2004; 66:
2017–2021.
26. Kramer H, Toto R, Peshock R et al. Association between chronic kidney
disease and coronary artery calcification: the Dallas Heart Study. J Am Soc
Nephrol 2005; 16: 507–513.
27. Arad Y, Goodman KJ, Roth M et al. Coronary calcification, coronary
disease risk factors, C-reactive protein and atherosclerotic cardiovascular
disease events: the St Francis Heart Study. J Am Coll Cardiol 2005; 46:
158–165.
28. Arad Y, Spadaro LA, Goodman K et al. Predictive value of electron
beam computed tomography of the coronary arteries 19-month
follow-up of 1173 asymptomatic subjects. Circulation 1996; 93:
1951–1953.
29. Arad Y, Spadaro LA, Goodman K et al. Prediction of coronary events with
electron beam computed tomography. J Am Coll Cardiol 2000; 36:
1253–1260.
30. Bielak LF, Rumberger JA, Sheedy II PF et al. Probabilistic model for
prediction of angiographically defined obstructive coronary artery
disease using electron beam computed tomography calcium score strata.
Circulation 2000; 102: 380–385.
31. Kondos GT, Hoff JA, Sevrukov A et al. Electron-beam tomography
coronary artery calcium and cardiac events: a 37-month follow-up of
5635 initially asymptomatic low- to intermediate-risk adults. Circulation
2003; 107: 2571–2576.
1398 Kidney International (2007) 72, 1394–1399
o r i g i n a l a r t i c l e JH Ix et al.: Fetuin-A and mortality in CKD
32. Park R, Detrano R, Xiang M et al. Combined use of computed tomography
coronary calcium scores and C-reactive protein levels in predicting
cardiovascular events in nondiabetic individuals. Circulation 2002; 106:
2073–2077.
33. Pletcher MJ, Tice JA, Pignone M et al. Using the coronary artery calcium
score to predict coronary heart disease events: a systematic review and
meta-analysis. Arch Intern Med 2004; 164: 1285–1292.
34. Cozzolino M, Galassi A, Biondi ML et al. Decreased serum fetuin-A levels
after a single haemodialysis session. Nephrol Dial Transplant 2007; 22:
290–291.
35. Greene T, Bourgoignie JJ, Habwe V et al. Baseline characteristics in the
Modification of Diet in Renal Disease Study. J Am Soc Nephrol 1993; 4:
1221–1236.
36. Klahr S, Levey AS, Beck GJ et al. The effects of dietary protein restriction
and blood-pressure control on the progression of chronic renal disease.
Modification of Diet in Renal Disease Study Group. N Engl J Med 1994;
330: 877–884.
37. Kusek JW, Coyne T, de Velasco A et al. Recruitment experience in the
full-scale phase of the Modification of Diet in Renal Disease Study.
Control Clin Trials 1993; 14: 538–557.
Kidney International (2007) 72, 1394–1399 1399
JH Ix et al.: Fetuin-A and mortality in CKD o r i g i n a l a r t i c l e
